Get the Stockscreener App
1.01
0.00%
0.00
Ocugen Inc stock is traded at $1.01, with a volume of 2.29M.
It is up +0.00% in the last 24 hours and down -1.94% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.01
Open:
$1.01
24h Volume:
2.29M
Relative Volume:
0.44
Market Cap:
$295.23M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-3.7407
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
-3.81%
1M Performance:
-1.94%
6M Performance:
+48.53%
1Y Performance:
-17.89%
1-Day Range:
$1.00
$1.05
1-Week Range:
$0.98
$1.06
52-Week Range:
$0.515
$1.40
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.01 | 324.80M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen Gains EMA Backing for Single Pivotal Trial to Support Stargardt Disease Gene Therapy Approval - MSN
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates - MSN
What makes Ocugen Inc. stock attractive todayWeekly Risk Summary & Long-Term Growth Stock Strategies - thegnnews.com
How Ocugen Inc. stock performs during market volatilityVolume Spike & Accurate Entry and Exit Point Alerts - thegnnews.com
Will Ocugen Inc. benefit from rising consumer demand2025 Geopolitical Influence & Free Accurate Trade Setup Notifications - thegnnews.com
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years - MSN
Will Ocugen Inc. Benefit From Broader Market BounceJuly 2025 Review & High Win Rate Trade Alerts - newsyoung.net
Is Ocugen Inc. part of any ETFMarket Weekly Review & Safe Entry Momentum Stock Tips - newsimpact.co.kr
Ocugen reports EMA positive advice for acceptability of OCU410ST - MSN
Can Ocugen Inc. benefit from deglobalization2025 Top Gainers & Verified Swing Trading Watchlists - sundaytimes.kr
EMA's CHMP Gives Ocugen the Green Light to Submit MAA for OCU410ST Based on GARDian3 Trial - CGTLive®
How to contact the Daily Bulletin - FinancialContent
Ocugen's Strategic Advancements and Financial Positioning Support Buy Rating - AInvest
Ocugen’s Strategic Advancements and Financial Positioning Underpin Buy Rating - TipRanks
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease - ir.ocugen.com
Acuity Inc. shares rise 1.01% premarket after Ocugen, Inc. receives positive scientific advice. - AInvest
Ocugen gets EMA backing on OCU410ST approval pathway for Stargardt gene therapy - MarketScreener
Ocugen, Inc. Announces Positive Scientific Advice from the Europ - GuruFocus
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST--Modifier Gene Therapy for Stargardt Disease | OCGN Stock News - GuruFocus
Ocugen gets EMA backing for single trial of Stargardt disease therapy - Investing.com
Ocugen's OCU410ST trial for Stargardt disease meets EMA's acceptability criteria. - AInvest
Ocugen, Inc. Announces Positive Scientific Advice from the - GlobeNewswire
Ocugen's Stargardt Disease Treatment Gets Fast-Track to EU Approval with Single Trial Plan - Stock Titan
Janus Henderson Group Plc shares rise 1.98% after-hours following $20 million investment in Ocugen, Inc. - AInvest
Ocugen Secures $20 Million in Direct Offering with Janus Henderson - MSN
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants - Ocugen
Ocugen raises $20 million in direct offering to Janus Henderson - Investing.com
Ocugen raises $20 million in direct offering to Janus Henderson By Investing.com - Investing.com South Africa
Ocugen Secures $20 Million in Registered Direct Offering, Extending Cash Runway into 2026 - AInvest
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants - MarketScreener
Ocugen Announces $20M Securities Purchase Agreement to Bolster Gene Therapy Programs - AInvest
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen Announces $20M Securities Purchase Agreement - TipRanks
Ocugen Announces $20 Million Registered Direct Offering of Common Stock and Warrants. - AInvest
Ocugen Secures $20 Million Investment from Janus Henderson, Projected Stock Price Upside - AInvest
Ocugen Raises $20M in Registered Direct Offering with Warrants for Potential $30M Boost. - AInvest
Ocugen's $20M Funding Move: Strategic Capital Raise or Warning Signal? - AInvest
Ocugen's $20M Raise: A Calculated Gamble in the Gene Therapy Arms Race? - AInvest
Will Ocugen Inc. outperform the market in YEARPre-Earnings Rally Picks - kangso.co.kr
Ocugen announces $20M registered direct offering of common stock, warrants - TipRanks
Ocugen's $20M Equity Raise and Warrant Offering: Strategic Capital Move or Dilution Risk? - AInvest
Ocugen raises $20 million in registered direct offering By Investing.com - Investing.com Australia
Ocugen raises $20 million in registered direct offering - Investing.com
Ocugen Raises $20M in Direct Offering of Common Stock and Warrants - AInvest
Ocugen Lands $50M Potential Financing Deal: Janus Henderson Backs Blindness Gene Therapy Pioneer - Stock Titan
CGTLive®’s Weekly Rewind – August 8, 2025 - CGTLive®
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):